Abstract Search

ea0042oc12 | (1) | Androgens2016

Rapid cycling high dose testosterone (Bipolar Androgen Therapy) as therapy for men with metastatic castrate-resistant prostate cancer (mCRPC)

Denmeade Samuel R. , Antonarakis Emmanuel , Paller Channing , Wang Hao , Teply Ben , Drake Charles , Carducci Michael , Luo Jun , Eisenberger Mario

Prostate cancer (PC) becomes resistant to chronic castration via an adaptive increase in androgen receptor (AR) axis activity. AR overexpression, however, is a liability that can be exploited therapeutically through rapid cycling between high supraphysiologic and low castrate levels of serum testosterone (T), (Bipolar Androgen Therapy (BAT)). In a pilot study, 14 men with CRPC treated with BAT showed a 50% PSA and objective response. A larger study was initiated in which asymp...

0 shares

ea0092ps1-06-02 | Thyroid Cancer clinical 1 | ETA2023

Long-Term outcomes following initial therapy in differentiated thyroid cancer (DTC) in china: DTCC 2nd stage study analysis 2014-2022

Ming Jie , Zhu Jing-Qiang , Sun Hui , Zhang Hao , Wang Jun , Xie Lei , Cheng Ruo-Chuan , Li Xing-Rui , Huang Tao

Objectives: We previously reported the outcome of 1-year follow-up of 2013 DTC patients in the DTCC (differentiated thyroid cancer in China) 1st stage Study. Using the retrospectively gathered information, we sought to observe the long-term follow-up and prognosis of these patients with DTC undergoing thyroid surgery.Methods: This multicenter, noninterventional study was conducted at eight tertiary hospitals across China. Data from the patient...

2 shares

Endocrine Abstracts

Rapid cycling high dose testosterone (Bipolar Androgen Therapy) as therapy for men with metastatic castrate-resistant prostate cancer (mCRPC)

Long-Term outcomes following initial therapy in differentiated thyroid cancer (DTC) in china: DTCC 2nd stage study analysis 2014-2022

BiosciAbstracts